RNAM
Avidity Biosciences
RNAM
RNAM
Delisted
RNAM was delisted on the 26th of February, 2026.
336 hedge funds and large institutions have $10.1B invested in Avidity Biosciences in 2025 Q4 according to their latest regulatory filings, with 150 funds opening new positions, 70 increasing their positions, 86 reducing their positions, and 81 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
17.02% less ownership
Funds ownership: 110.32% → 93.3% (-17%)
19% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 86
76% less call options, than puts
Call options by funds: $64.3M | Put options by funds: $264M
Holders
336
Holding in Top 10
31
Calls
$64.3M
Puts
$264M
Top Buyers
| 1 | +$390M | |
| 2 | +$389M | |
| 3 | +$282M | |
| 4 |
BlackRock
New York
|
+$236M |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$159M |
Top Sellers
| 1 | -$1.38B | |
| 2 | -$623M | |
| 3 | -$603M | |
| 4 |
RI
RTW Investments
New York
|
-$496M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$490M |
